Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Nikolas Herold, Sean G. Rudd, Kumar Sanjiv, Juliane Kutzner, Julia Bladh, Cynthia B. J. Paulin, Thomas Helleday, Jan-Inge Henter & Torsten Schaller. (2017) SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle 16:11, pages 1029-1038.
Read now
Read now
Patrizia Ferraboschi, Samuele Ciceri & Paride Grisenti. (2017) Synthesis of Antitumor Fluorinated Pyrimidine Nucleosides. Organic Preparations and Procedures International 49:2, pages 69-154.
Read now
Read now
Godefridus J Peters & Richard J Honeywell. (2015) Drug transport and metabolism of novel anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 11:5, pages 661-663.
Read now
Read now
Articles from other publishers (46)
Alireza Abbaspour, Mehdi Dehghani, Mahtab Setayesh, Marjan Tavakkoli, Hossein Ali Rostamipour, Marziyeh Ghorbani, Mani Ramzi, Shapour Omidvari, Fatemeh Moosavi & Omidreza Firuzi. (2023) Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients. Cancer Chemotherapy and Pharmacology 92:6, pages 475-483.
Crossref
Crossref
Nasrullah Jan, Hassan Shah, Safiullah Khan, Faiza Nasar, Asadullah Madni, Syed Faisal Badshah, Ahsan Ali & Mohammad F. Bostanudin. (2023) Old drug, new tricks: polymer-based nanoscale systems for effective cytarabine delivery. Naunyn-Schmiedeberg's Archives of Pharmacology.
Crossref
Crossref
Yasmin Cura, Almudena Sánchez-Martín, Noelia Márquez-Pete, Encarnación González-Flores, Fernando Martínez-Martínez, Cristina Pérez-Ramírez & Alberto Jiménez-Morales. (2023) Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients. Pharmaceutics 15:11, pages 2548.
Crossref
Crossref
Melanie Donnette, Mourad Hamimed, Joseph Ciccolini, Guillaume Sicard, Florian Correard, Laure Farnault, L'Houcine Ouafik, Geoffroy Venton & Raphaëlle Fanciullino. (2023)
Cytidine deaminase status as a marker of response to azacytidine treatment in
MDS
and
AML
patients
. British Journal of Haematology.
Crossref
Crossref
Kyung U. Hong, Afi H. Tagnedji, Mark A. Doll, Kennedy M. Walls & David W. Hein. (2022) Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells. Journal of Cancer Research and Clinical Oncology 149:8, pages 5047-5060.
Crossref
Crossref
Yasmin Cura, Cristina Pérez-Ramírez, Almudena Sánchez-Martín, Cristina Membrive-Jimenez, María Isabel Valverde-Merino, Encarnación González-Flores & Alberto Jiménez Morales. (2023) Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review. Cancers 15:6, pages 1821.
Crossref
Crossref
Nina Urbelienė, Matas Tiškus, Giedrė Tamulaitienė, Renata GasparavičiūtėRingailė Lapinskaitė, Vykintas Jauniškis, Jurgis SūdžiusRita MeškienėDaiva Tauraitė, Emilija SkrodenytėGintaras UrbelisJustas Vaitekūnas & Rolandas Meškys. (2023)
Cytidine deaminases catalyze the conversion of
N
(
S
,
O
)
4
-substituted pyrimidine nucleosides
. Science Advances 9:5.
Crossref
Crossref
Hatasu Kobayashi, Yurie Mori, Sharif Ahmed, Yuichiro Hirao, Shinya Kato, Shosuke Kawanishi, Mariko Murata & Shinji Oikawa. (2022)
Oxidative DNA Damage by
N
4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
. The Journal of Infectious Diseases.
Crossref
Crossref
Sha Li, Shi Zeng, Bo-ping Wei, Qiang Wu, Chang Liu & Pei-ying Song. (2022) Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B 1200, pages 123275.
Crossref
Crossref
Sreerama Rajasekhar, Soumyadip Das, M. M. Balamurali & Kaushik Chanda. (2021)
Therapeutic Inhibitory Activities of
N
‐Hydroxy Derived Cytidines: A Patent Overview
. ChemistrySelect 6:48, pages 13786-13808.
Crossref
Crossref
Naoyuki Kamatani, H.A. Jinnah, Raoul C.M. Hennekam & André B.P. van Kuilenburg. 2021. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics
183
234
.
Natalie R. Neumann & Christopher O. Hoyte. 2021. Oncologic Emergency Medicine. Oncologic Emergency Medicine
739
749
.
M. Van Nuland, H. Rosing, B. Thijssen, J.A. Burgers, A.D.R. Huitema, S. Marchetti, J.H.M. Schellens & J.H. Beijnen. (2020) Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. Clinical Pharmacology in Drug Development 9:8, pages 929-937.
Crossref
Crossref
Jun Young Park, Ju Ri Chae, Ye Lim Cho, Youndong Kim, Dasom Lee, Jeong Kyun Lee & Won Jun Kang. (2020) Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer. Pharmaceutics 12:10, pages 985.
Crossref
Crossref
Florent Ferrer, Raphaelle Fanciullino, Gérard Milano & Joseph Ciccolini. (2020) Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations. Clinical Pharmacology & Therapeutics 108:3, pages 458-470.
Crossref
Crossref
Appolinaire A. Olou, Ryan J. King, Fang Yu & Pankaj K. Singh. (2020) MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism. Oncogene 39:16, pages 3381-3395.
Crossref
Crossref
Ruginn Catarata, Nilab Azim, Santanu Bhattacharya & Lei Zhai. (2020) Controlled drug release from polyelectrolyte–drug conjugate nanoparticles. Journal of Materials Chemistry B 8:14, pages 2887-2894.
Crossref
Crossref
Tormod Bjånes, Spiros Kotopoulis, Elisa Thodesen Murvold, Tina Kamčeva, Bjørn Tore Gjertsen, Odd Helge Gilja, Jan Schjøtt, Bettina Riedel & Emmet McCormack. (2020) Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics 12:2, pages 141.
Crossref
Crossref
Audrey Frances & Pierre Cordelier. (2020) The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?. Molecular Therapy 28:2, pages 357-366.
Crossref
Crossref
SABINE KARAM, VICTORIA GUTGARTS & ILYA GLEZERMAN. 2020. Onco-Nephrology. Onco-Nephrology
183
196.e7
.
Godefridus J. Peters. 2020. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies
1
33
.
Jing Li, Dan Xu, Jian Huang, Yan-Na Wang, Xiao-Ping Ma, Zhi-Yi Lin & Ping Gong. (2019) Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer. The International Journal of Biological Markers 34:4, pages 389-397.
Crossref
Crossref
Melanie Donnette, Caroline Solas, Madeleine Giocanti, Geoffroy Venton, Laure Farnault, Yael Berda-Haddad, Le Thi Thu Hau, Régis Costello, L'Houcine Ouafik, Bruno Lacarelle, Joseph Ciccolini & Raphaëlle Fanciullino. (2019) Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. Journal of Chromatography B 1126-1127, pages 121770.
Crossref
Crossref
R. Cohen, L. H. Preta, V. Joste, E. Curis, O. Huillard, A. Jouinot, C. Narjoz, A. Thomas‐Schoemann, A. Bellesoeur, M. Tiako Meyo, J. Quilichini, D. Desaulle, I. Nicolis, A. Cessot, M. Vidal, F. Goldwasser, J. Alexandre & B. Blanchet. (2019) Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. British Journal of Clinical Pharmacology 85:6, pages 1227-1238.
Crossref
Crossref
Wenhui Qiu, Shuai Liu, Feng Yang, Peiyao Dong, Ming Yang, Minghung Wong & Chunmiao Zheng. (2019) Metabolism disruption analysis of zebrafish larvae in response to BPA and BPA analogs based on RNA-Seq technique. Ecotoxicology and Environmental Safety 174, pages 181-188.
Crossref
Crossref
Duo Liu, Xiang Li, Xuehua Li, Mingyan Zhang, Juan Zhang, Dan Hou, Zhiqiang Tong & Mei Dong. (2019) CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. Cancer Chemotherapy and Pharmacology 83:5, pages 939-949.
Crossref
Crossref
Nikolaos Tsesmetzis, Cynthia Paulin, Sean Rudd & Nikolas Herold. (2018) Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers 10:7, pages 240.
Crossref
Crossref
Xin Du, Yue-Yun Lai, Zhijian Xiao, Ting Liu, Yu Hu, Aining Sun, Xiao Li, Zhi-Xiang Shen, Jie Jin, Li Yu, Eric Laille, Qian Dong, Stephen Songer & C.L. Beach. (2018) Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. Asia-Pacific Journal of Clinical Oncology 14:3, pages 270-278.
Crossref
Crossref
John P. Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf & Daniel H. Palmer. (2018) Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology & Hepatology 15:6, pages 333-348.
Crossref
Crossref
Raphaelle FanciullinoLaure FarnaultMélanie DonnetteDiane-Charlotte ImbsCatherine Roche, Geoffroy VentonYael Berda-Haddad, Vadim IvanovJoseph Ciccolini, L’Houcine Ouafik, Bruno Lacarelle & Regis Costello. (2018) CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Advances 2:5, pages 462-469.
Crossref
Crossref
Jung-Suk Choi, Casey Seol Kim & Anthony Berdis. (2018) Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. Cancer Research 78:4, pages 1083-1096.
Crossref
Crossref
Siu W. Lam, Vincent van der Noort, Tahar van der Straaten, Aafke H. Honkoop, Godefridus J. Peters, Henk-Jan Guchelaar & Epie Boven. (2018) Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological Research 128, pages 122-129.
Crossref
Crossref
Beata Hryciuk, Bartosz Szymanowski, Anna Romanowska, Ewa Salt, Bartosz Wasąg, Bartłomiej Grala, Jacek Jassem & Renata Duchnowska. (2017) Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. Oncology Letters.
Crossref
Crossref
Cindy Serdjebi, Florence Gattacceca, Jean-François Seitz, Francine Fein, Johan Gagnière, Eric François, Abakar Abakar-Mahamat, Gael Deplanque, Madani Rachid, Bruno Lacarelle, Joseph Ciccolini & Laetitia Dahan. (2017) Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach. Therapeutic Drug Monitoring 39:3, pages 290-296.
Crossref
Crossref
Pedro Morales-Ramírez, Teresita Vallarino-Kelly & Virginia Cruz-Vallejo. (2017) Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine. Cancer Chemotherapy and Pharmacology 79:5, pages 843-853.
Crossref
Crossref
Hamza Mameri, Ivan Bièche, Didier Meseure, Elisabetta Marangoni, Géraldine Buhagiar-Labarchède, André Nicolas, Sophie Vacher, Rosine Onclercq-Delic, Vinodh Rajapakse, Sudhir Varma, William C. Reinhold, Yves Pommier & Mounira Amor-Guéret. (2017) Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. Clinical Cancer Research 23:8, pages 2116-2126.
Crossref
Crossref
Daphne Bertholee, Jan Gerard Maring & André B. P. van Kuilenburg. (2016) Genotypes Affecting the Pharmacokinetics of Anticancer Drugs. Clinical Pharmacokinetics 56:4, pages 317-337.
Crossref
Crossref
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Crossref
S.W. Lam, H.J. Guchelaar & E. Boven. (2016) The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treatment Reviews 50, pages 9-22.
Crossref
Crossref
Ruud H. Wijdeven, Baoxu Pang, Yehuda G. Assaraf & Jacques Neefjes. (2016) Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. Drug Resistance Updates 28, pages 65-81.
Crossref
Crossref
Joseph Ciccolini, Cindy Serdjebi, Godefridus J. Peters & Elisa Giovannetti. (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemotherapy and Pharmacology 78:1, pages 1-12.
Crossref
Crossref
Chiara Rampazzo, Maria Grazia Tozzi, Charles Dumontet & Lars Petter Jordheim. (2015) The druggability of intracellular nucleotide-degrading enzymes. Cancer Chemotherapy and Pharmacology 77:5, pages 883-893.
Crossref
Crossref
Dan Wang, Qingqing Xiao, Wanqiu Yang, Wei Qian & Jin Yang. (2016) HPLC-MS/MS method for the simultaneous determination of MB07133 and its metabolites, cytarabine and arabinofuranosyluracil, in rat plasma. Journal of Pharmaceutical and Biomedical Analysis 120, pages 228-234.
Crossref
Crossref
Simon Gemble, Géraldine Buhagiar-Labarchède, Rosine Onclercq-Delic, Denis Biard, Sarah Lambert & Mounira Amor-Guéret. (2016) A balanced pyrimidine pool is required for optimal Chk1 activation to prevent ultrafine anaphase bridge formation. Journal of Cell Science.
Crossref
Crossref
Laura Taddia, Domenico D’Arca, Stefania Ferrari, Chiara Marraccini, Leda Severi, Glauco Ponterini, Yahuda G. Assaraf, Gaetano Marverti & Maria Paola Costi. (2015) Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resistance Updates 23, pages 20-54.
Crossref
Crossref
Cindy Serdjebi, Johan Gagnière, Jérôme Desramé, Francine Fein, Rosine Guimbaud, Eric François, Thierry André, Jean-François Seitz, Carole Montérymard, Dominique Arsene, Julien Volet, Abakar Abakar-Mahamat, Thierry Lecomte, Véronique Guerin-Meyer, Jean-Louis Legoux, Gaël Deplanque, Pierre Guillet, Joseph Ciccolini, Côme Lepage & Laetitia Dahan. (2015) FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. PLOS ONE 10:8, pages e0135907.
Crossref
Crossref